Document resource
Although myasthenia gravis (MG) primarily manifests as weakness of oculo-bulbar, axial and appendicular muscles, the disease and its treatments are associated with many comorbid conditions that impact patients’ quality of life. Patients frequently experience secondary autoimmunity, cardiovascular and endocrine dysfunction, fatigue, sleep and mental health disorders. MG and its treatments can also be an important source of social and economic burden on patients. This review aims to elaborate on the multi-morbid nature of MG and to provide an approach for recognising and managing relevant comorbidities with an emphasis on preventative health.